Recombinant PCSK9 (Lodelcizumab Biosimilar) antibody
The Mammalian Cells Monoclonal anti-PCSK9 (Lodelcizumab Biosimilar) antibody is suitable to detect PCSK9 (Lodelcizumab Biosimilar) in samples from Human. It has been validated for ELISA.
Catalog No. ABIN7488018
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant PCSK9 (Lodelcizumab Biosimilar) antibody (ABIN7488018)
Target
PCSK9 (Lodelcizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This PCSK9 (Lodelcizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Lodelcizumab Biosimilar - Anti-PCSK9 mAb
-
Characteristics
- Antibody Type: IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- PCSK9 (Lodelcizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
LGT209,NVP-LGT209
Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. -
CAS-No
- 1355338-54-3
Target
-
You are here:
